Vyome Holdings HIND
Vyome Holdings FY 2021: revenue $13.6M, up 756%; diluted EPS −$21,374,829.00
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001558370-22-005238
Key figures from this report
These are the numbers Vyome Holdings reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$13.6M+756% from $1.6M in FY 202010-K income statement, on EDGAR
- Net income−$61.9MAgainst −$12.3M in FY 202010-K income statement, on EDGAR
- Diluted EPS−$21,374,829.00Against −$23,726,060.19 in FY 2020. Split-adjusted, as the tables show it; the filing reported −$5.0010-K income statement, on EDGAR
- Cash and cash equivalents$22.8M+483% from $3.9M in FY 202010-K balance sheet, on EDGAR
- Cash from operations−$15.4MAgainst −$10.4M in FY 202010-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- AIM ImmunoTech AIM public float $6M, Jun 30, 2025
- Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
- PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025
- Natural Alternatives International NAII public float $6M, Dec 31, 2025
- LFTD Partners LIFD public float $6M, Jun 30, 2025
